Report from Incubate Policy Lab and Charles River Associates Finds Price Controls Would Decrease Investment in Critical Therapeutic Areas Washington, D.C., Nov. 18, 2021 (GLOBE NEWSWIRE) -- Today, Incubate Policy Lab and Charles River Associates published a report detailing how investment into therapies for rare diseases and oncology...

Report from Incubate Policy Lab and Charles River Associates Finds Congressional Budget Office Underestimates Negative Impact of Drug Pricing Legislation Washington, D.C., Oct. 20, 2021 (GLOBE NEWSWIRE) -- Today, Incubate Policy Lab and Charles River Associates published a report demonstrating that a leading proposal that would allow the federal...